New Options for HER2+ Breast Cancer
Symposium
Symposium

New Options for HER2+ Breast Cancer

Building on Success

Not a member of My prIME? Join now for instant access.

Meeting Overview

Join us in Munich to learn about the latest developments in HER2+ breast cancer from top experts in the field. Adjuvant strategies to improve patient outcomes and management of metastatic disease will be discussed. Attendees will have the opportunity to ask questions and interact with the expert faculty.

ESMO 2018 Industry Satellite Symposium

Date and Location

Sunday, 21 October 2018
13.00 – 14.30

ICM – Room 1
Messe Munich
Munich, Germany

Date/Time

Date/Time

Sunday, 21 October 2018
13.00 – 14.30

Location

Location

Munich, Germany

IME

IME

Sunday, 21 October 2018

13.00 Welcome and introduction
Hope S. Rugo, MD, FASCO
13.02 HER2+ breast cancer: Clinical scenarios and treatment recommendations
Hope S. Rugo, MD, FASCO
13.10 The changing natural history of HER2+ breast cancer
Michael Untch, MD, PhD
13.25 Preventing recurrent disease: How can we bring new adjuvant therapeutic opportunities to the clinic?
Miguel Martín, MD, PhD
13.45 HER2+ metastatic breast cancer in 2018: Is this as good as it gets?
John Crown, MD, FRCPI
14.05 Panel discussion
All faculty
14.20 Bringing it all together: Clinical application of recent developments
All faculty
14.28 prIME Points™
Hope S. Rugo, MD, FASCO
14.30 Adjourn

 

Chair

  • Hope S. Rugo, MD, FASCOUniversity of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California, United States

Faculty

  • John Crown, MD, FRCPISt. Vincent's University Hospital
    Dublin, Ireland
  • Miguel Martín, MD, PhDComplutense University
    Hospital General Universitario Gregorio Marañon
    Madrid, Spain
  • Michael Untch, MD, PhDHELIOS Klinikum Berlin-Buch
    Berlin, Germany

This educational activity is specifically designed to educate medical oncologists, breast oncologists, and other healthcare providers who treat patients with breast cancer.

After successful completion of this educational activity, participants should be able to:

  • Describe the evolution of HER2+ breast cancer in the current era of HER2-targeted treatments and the remaining areas of unmet medical need
  • Evaluate the results of recent clinical trials in HER2+ early breast cancer that explore the evolution of adjuvant treatment strategies and the need for a risk-adapted strategy
  • Assess recent developments in HER2-targeted treatment and the opportunities provided by novel agents for HER2+ metastatic breast cancer
  • Identify supportive care interventions to minimize adverse events with HER2-targeted therapy

This educational activity is supported by a grant from Puma Biotechnology.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.